SANN — Santhera Pharmaceuticals Holding AG Income Statement
0.000.00%
Last trade - 00:00- CH₣163.59m
- CH₣163.29m
- CH₣39.12m
Annual income statement for Santhera Pharmaceuticals Holding AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 15 | -1.59 | 7.47 | 103 | 39.1 |
| Cost of Revenue | |||||
| Gross Profit | 4.58 | -5.36 | 3.88 | 100 | 23.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 68.1 | 55.4 | 59.4 | 34.8 | 72.2 |
| Operating Profit | -53.1 | -56.9 | -52 | 68.6 | -33.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -67.5 | -54.8 | -70.6 | 54.8 | -41.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -67.7 | -55.6 | -71.1 | 54.8 | -42 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -67.7 | -55.6 | -71.1 | 54.8 | -42 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -67.7 | -55.6 | -71.1 | 54.8 | -42 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -50.8 | -16.3 | -11 | 3.42 | -3.69 |